Antineoplaston Therapy in Treating Children With Visual Pathway Glioma
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Current therapies for children with visual pathway gliomas, which are not amenable
to or have not responded to standard therapy, provide limited benefit to the patient. The
anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the
treatment of children with visual pathway gliomas, which are not amenable to or have not
responded to standard therapy.
PURPOSE: This study is being performed to determine the effects (good and bad) that
Antineoplaston therapy has on children with visual pathway gliomas, which are not amenable to
or have not responded to standard therapy.